Literature DB >> 10878544

Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue.

A Hobisch1, H Rogatsch, A Hittmair, D Fuchs, G Bartsch, H Klocker, G Bartsch, Z Culig.   

Abstract

Interleukin-6 (IL-6) is a pleiotropic cytokine that interacts with its receptor in prostate cells, thus regulating proliferative response and differentiation. It also activates the human androgen receptor in prostate cancer cell lines. In order to assess the significance of these findings in vivo, the expression of key elements of the IL-6 signalling pathway, IL-6 and its receptor, was investigated in tissue samples obtained on radical prostatectomy from prostate cancer patients. IL-6 immunohistochemistry was performed on 17 frozen prostate cancer specimens. IL-6 receptor immunostaining was evaluated in 21 paraffin-embedded prostate tumour specimens. In both groups, adjacent areas of high-grade prostatic intraepithelial neoplasia and benign tissue were also investigated. In benign prostatic epithelium, IL-6 was localized predominantly in basal cells, whereas in prostate cancer tissues more IL-6-positive glandular cells were identified. No IL-6 expression was detected in stromal cells on immunohistochemistry, although IL-6 protein was measured in the supernatants obtained from cultured stromal cells by ELISA. IL-6 receptor was expressed in benign prostatic tissue in both epithelial and stromal cells. Furthermore, IL-6 receptor expression was observed in all tumour specimens investigated and the majority of Gleason patterns analysed had more than 50% of cells showing a positive reaction. IL-6 and IL-6 receptor expression patterns in high-grade prostatic intraepithelial neoplasia lesions were similar to those observed in tumour tissues. Taken together, the results of the present study imply that there are paracrine and autocrine IL-6 loops in benign and neoplastic prostate. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10878544     DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH633>3.0.CO;2-X

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  54 in total

1.  The profile of prostate epithelial cytokines and its impact on sera prostate specific antigen levels.

Authors:  Yosra Bouraoui Mechergui; Awatef Ben Jemaa; Chekib Mezigh; Benito Fraile; Nawfel Ben Rais; Ricardo Paniagua; Mar Royuela; Ridha Oueslati
Journal:  Inflammation       Date:  2009-04-28       Impact factor: 4.092

2.  A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells.

Authors:  Shu-Han Yu; Qizhi Zheng; David Esopi; Anne Macgregor-Das; Jun Luo; Emmanuel S Antonarakis; Charles G Drake; Robert Vessella; Colm Morrissey; Angelo M De Marzo; Karen S Sfanos
Journal:  Cancer Immunol Res       Date:  2015-06-05       Impact factor: 11.151

3.  Co-expression of interleukin-6 and human growth hormone in apparently normal prostate biopsies that ultimately progress to prostate cancer using low pH, high temperature antigen retrieval.

Authors:  M D Slater; C R Murphy
Journal:  J Mol Histol       Date:  2006-06-29       Impact factor: 2.611

Review 4.  Prostate cancer and inflammation: the evidence.

Authors:  Karen S Sfanos; Angelo M De Marzo
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

5.  Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR).

Authors:  Christoph Garbers; Fabian Kuck; Samadhi Aparicio-Siegmund; Kirstin Konzak; Mareike Kessenbrock; Annika Sommerfeld; Dieter Häussinger; Philipp A Lang; Dirk Brenner; Tak W Mak; Stefan Rose-John; Frank Essmann; Klaus Schulze-Osthoff; Roland P Piekorz; Jürgen Scheller
Journal:  Cell Cycle       Date:  2013-09-18       Impact factor: 4.534

Review 6.  Molecular mechanisms of castration-resistant prostate cancer progression.

Authors:  Smitha S Dutt; Allen C Gao
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

7.  Propionibacterium acnes infection induces upregulation of inflammatory genes and cytokine secretion in prostate epithelial cells.

Authors:  Johanna B Drott; Oleg Alexeyev; Patrik Bergström; Fredrik Elgh; Jan Olsson
Journal:  BMC Microbiol       Date:  2010-04-26       Impact factor: 3.605

8.  Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.

Authors:  Lei Gu; Pooja Talati; Paraskevi Vogiatzi; Ana L Romero-Weaver; Junaid Abdulghani; Zhiyong Liao; Benjamin Leiby; David T Hoang; Tuomas Mirtti; Kalle Alanen; Michael Zinda; Dennis Huszar; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2014-02-27       Impact factor: 6.261

9.  Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling.

Authors:  Junichi Inokuchi; Alice Lau; Darren R Tyson; David K Ornstein
Journal:  Carcinogenesis       Date:  2009-04-07       Impact factor: 4.944

10.  Pathogenesis of prostate cancer and hormone refractory prostate cancer.

Authors:  J S Girling; H C Whitaker; I G Mills; D E Neal
Journal:  Indian J Urol       Date:  2007-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.